Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan Takashi Kadowaki Masakazu Haneda Hiroshi Ito Kazuyo Sasaki Yuka Yamada 10.6084/m9.figshare.11993877.v2 https://adisjournals.figshare.com/articles/figure/Long-Term_Safety_and_Efficacy_of_Teneligliptin_in_Elderly_Type_2_Diabetes_Patients_Subgroup_Analysis_of_a_3-Year_Post-Marketing_Surveillance_in_Japan/11993877 <p>The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p> 2020-04-14 15:28:26 Diabetes Dipeptidyl peptidase-4 inhibitor Elderly patients Post-marketing surveillance Real-world Teneligliptin Type 2 diabetes mellitus Plain Language Summary